Telesis Bio (NASDAQ:TBIO) Shares to Reverse Split on Thursday, May 9th

Telesis Bio, Inc. (NASDAQ:TBIO)’s stock is going to reverse split on the morning of Thursday, May 9th. The 1-18 reverse split was announced on Thursday, May 9th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, May 9th.

Telesis Bio Stock Down 10.0 %

TBIO traded down $0.03 during midday trading on Tuesday, reaching $0.31. The company’s stock had a trading volume of 808,045 shares, compared to its average volume of 575,848. The stock’s 50-day moving average is $0.44 and its 200-day moving average is $0.45. The firm has a market capitalization of $9.21 million, a price-to-earnings ratio of -0.19 and a beta of 1.93. Telesis Bio has a 1 year low of $0.28 and a 1 year high of $3.01. The company has a current ratio of 3.71, a quick ratio of 3.22 and a debt-to-equity ratio of 22.76.

Telesis Bio (NASDAQ:TBIO) last issued its earnings results on Thursday, March 28th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. Telesis Bio had a negative net margin of 173.78% and a negative return on equity of 176.47%. The firm had revenue of $6.98 million for the quarter.

Telesis Bio Company Profile

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits which contains the necessary building blocks and reagents, including proprietary gibson assembly branded reagents, for specific synthetic biology workflow applications.